Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
Health Tools
 Exercise and Fitness Guide
 Diet & Fitness Q&A
 Food Guide
 Diet Reviews
 Fitness and Family
Featured Conditions
 Diet & Exercise
 Food & Fitness
 High Blood Pressure
 Cholesterol
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
 Printer Friendly  Send to a Friend

New Weight-Loss Drug Shows Promise in Early Study

But adverse effects include gastrointestinal problems, anxiety

By Kathleen Doheny
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Ankle Sprains
Antioxidants
More...

Related Healthscout Videos
 border=
Nutrition and Cancer
Nutrition and Osteoporosis
Importance of Good Nutrition
Critical Nutrition
More...

Related Drug Information
 border=
Klor-Con
Klor-Con ER
More...

Related News Articles
 border=
Substitutions Make Holiday Fare Healthier
High Blood Pressure Stalks Many Americans
Health Tip: Signs of Celiac Disease in Children
FDA Approves New Drug for Severe Epilepsy
More...

TUESDAY, Jan. 8 (HealthDay News) -- An experimental weight-loss drug helped people shed pounds, but its adverse effects included gastrointestinal distress and psychiatric problems, scientists report.

Called taranabant, the drug was developed by Merck Research Laboratories, which funded the new research published in the January issue of Cell Metabolism.

Text Continues Below



"It suppresses food intake and increases your metabolism," explained Dr. Steven Heymsfield, global director of scientific affairs, obesity, for Merck Research.

The drug works by blocking the same pleasure centers in the brain that are triggered when marijuana smokers get hungry. Blocking these cannabinoid receptors reduces hunger and helps people lose weight, the researchers said.

Taranabant is in the same class of drugs as rimonabant (Acomplia), which the U.S. Food and Drug Administration has not yet approved due to concerns about the risk of suicidal thoughts among some users. Rimonabant is on the market in Europe, however.

In the new study on taranabant, "no suicidal thoughts were reported," Heymsfield said. But the question was not asked, he added, in a systemic way. For a larger, upcoming trial, it will be, he noted.

In this latest study, Heymsfield's team assigned 533 obese patients to receive either a placebo or one of four taranabant doses: 0.5, 2, 4 or 6 milligrams daily. A total of 358 patients finished the 12-week study.

While the placebo group lost about 2.6 pounds during the study, the 6-milligram taranabant group lost the most.

"Those who took the 6-milligram dose every day for 12 weeks lost about 11 pounds," Heymsfield said. They also followed a reduced-calorie eating plan but had no specific exercise plan.

In a separate study reported by the same group of scientists in the journal, the researchers gave 36 overweight or obese people a placebo or a single dose of either 4 milligrams or 12 milligrams of taranabant, or 30 milligrams of another weight-loss drug called sibutramine (Meridia). Then they tracked food intake over the next 24 hours.

Page:  1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 1/8/2008

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





SOURCES: Steven R. Smith, M.D., head, public affairs committee, the Obesity Society, and professor and assistant to the associate director for clinical research, Pennington Biomedical ResearchCenter, Baton Rouge, La.; Steven Heymsfield, M.D., global director, scientific affairs, obesity, Merck Research Laboratories, Rahway, N.J.; January 2008, Cell Metabolism


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.